枸橼酸铁与静脉蔗糖铁对CKD-MBD大鼠模型矿物质、骨及铁稳态标志物的影响
在中等程度CKD的Cy/+雄性大鼠模型中,比较10周2%枸橼酸铁(FC)与静脉蔗糖铁对CKD-MBD、铁稳态及氧化应激的影响。FC降低血磷、完整FGF23及C端FGF23趋势,FC与静脉铁均使主动脉和心脏钙化降至正常水平,两种铁剂均未增加氧化应激。
要点
- FC降低CKD大鼠血磷、完整FGF23,C端FGF23有降低趋势(P=0.07)。
- FC与静脉蔗糖铁均使主动脉和心脏钙化降至与正常大鼠相似水平。
- FC提高转铁蛋白饱和度,两种铁剂均未使氧化应激高于未治疗CKD大鼠。
核心结论
- 口服FC改善磷稳态、部分铁相关参数及FGF23的产生与裂解。
- 低剂量静脉蔗糖铁对心血管钙化和骨的间歇性效应需在中等至晚期CKD中进一步探索。
研究设计与样本
- 大鼠中等程度CKD模型(Cy/+雄性大鼠)与未治疗正常同窝大鼠,干预10周。
- 比较2%FC与静脉蔗糖铁,结局包括CKD-MBD、铁稳态和氧化应激的综合评估。
主要发现
- CKD大鼠存在氮质血症、血磷升高、甲状旁腺激素升高和FGF23升高。
- 与未治疗CKD大鼠相比,FC治疗使血磷、完整FGF23降低,C端FGF23有降低趋势(P=0.07)。
- FC和静脉铁均使主动脉和心脏钙化降至与正常动物相似水平。
- 与正常动物相比,CKD动物骨转换更高、骨小梁体积更低,矿化无差异,两种铁治疗均未影响这些指标。
- 静脉铁治疗大鼠的皮质骨和骨力学性能与正常动物相似;FC使转铁蛋白饱和度较未治疗CKD和正常大鼠升高。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出低剂量静脉蔗糖铁对心血管钙化和骨的间歇性效应需在中等至晚期CKD中进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) are common and begin early in CKD. Limited studies have concurrently compared the effects of ferric citrate (FC) versus intravenous (IV) iron on CKD-MBD and iron homeostasis in moderate CKD. METHODS: We tested the effects of 10 weeks of 2% FC versus IV iron sucrose in rats with moderate CKD (Cy/+ male rat) and untreated normal (NL) littermates. Outcomes included a comprehensive assessment of CKD-MBD, iron homeostasis and oxidative stress. RESULTS: CKD rats had azotemia, elevated phosphorus, parathyroid hormone and fibroblast growth factor-23 (FGF23). Compared with untreated CKD rats, treatment with FC led to lower plasma phosphorus, intact FGF23 and a trend (P = 0.07) toward lower C-terminal FGF23. FC and IV iron equally reduced aorta and heart calcifications to levels similar to NL animals. Compared with NL animals, CKD animals had higher bone turnover, lower trabecular volume and no difference in mineralization; these were unaffected by either iron treatment. Rats treated with IV iron had cortical and bone mechanical properties similar to NL animals. FC increased the transferrin saturation rate compared with untreated CKD and NL rats. Neither iron treatment increased oxidative stress above that of untreated CKD. CONCLUSIONS: Oral FC improved phosphorus homeostasis, some iron-related parameters and the production and cleavage of FGF23. The intermittent effect of low-dose IV iron sucrose on cardiovascular calcification and bone should be further explored in moderate-advanced CKD.
引用
- Biruete A, Metzger CE, Chen NX, et al. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrol Dial Transplant. 2022. PMID: 35482713. doi:10.1093/ndt/gfac162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。